Bank of New York Mellon Corp acquired a new stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report) in the 2nd quarter, Holdings Channel.com reports. The fund acquired 454,464 shares of the company’s stock, valued at approximately $1,018,000.
A number of other large investors have also added to or reduced their stakes in TSHA. Victory Capital Management Inc. acquired a new position in Taysha Gene Therapies in the 4th quarter valued at approximately $28,000. Dynamic Technology Lab Private Ltd bought a new position in Taysha Gene Therapies during the 4th quarter worth $31,000. Cannon Global Investment Management LLC bought a new position in Taysha Gene Therapies during the 1st quarter worth $69,000. China Universal Asset Management Co. Ltd. grew its position in shares of Taysha Gene Therapies by 66.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 35,908 shares of the company’s stock valued at $103,000 after buying an additional 14,286 shares during the last quarter. Finally, Chicago Partners Investment Group LLC raised its position in shares of Taysha Gene Therapies by 21.4% during the fourth quarter. Chicago Partners Investment Group LLC now owns 134,851 shares of the company’s stock worth $239,000 after acquiring an additional 23,740 shares during the last quarter. Institutional investors own 77.70% of the company’s stock.
Taysha Gene Therapies Price Performance
Shares of NASDAQ TSHA opened at $2.15 on Friday. The firm has a market capitalization of $440.62 million, a P/E ratio of -4.39 and a beta of 0.41. The firm’s 50-day moving average price is $2.20 and its 200-day moving average price is $2.59. The company has a current ratio of 5.22, a quick ratio of 5.22 and a debt-to-equity ratio of 0.35. Taysha Gene Therapies, Inc. has a 1-year low of $1.27 and a 1-year high of $4.32.
Insider Activity
In other news, major shareholder Paul B. Manning bought 1,333,333 shares of the business’s stock in a transaction that occurred on Thursday, June 27th. The shares were bought at an average cost of $2.25 per share, for a total transaction of $2,999,999.25. Following the acquisition, the insider now directly owns 1,333,333 shares in the company, valued at $2,999,999.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.70% of the company’s stock.
Wall Street Analyst Weigh In
Several brokerages recently commented on TSHA. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, June 20th. Piper Sandler cut their price target on shares of Taysha Gene Therapies from $9.00 to $7.00 and set an “overweight” rating on the stock in a research report on Monday, July 1st. Canaccord Genuity Group decreased their price target on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. JMP Securities reissued a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. Finally, Needham & Company LLC decreased their target price on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $6.38.
Check Out Our Latest Stock Report on TSHA
About Taysha Gene Therapies
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Read More
- Five stocks we like better than Taysha Gene Therapies
- How Can Investors Benefit From After-Hours Trading
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- What does consumer price index measure?
- MarketBeat Week in Review – 9/16 – 9/20
- How to Use the MarketBeat Excel Dividend Calculator
- Don’t Miss These 3 Retail Stocks for Fall Gains
Want to see what other hedge funds are holding TSHA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report).
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.